


PHARMACEUTICAL 2021

AbbVie Inc. Rank 20 of 409







RealRate

PHARMACEUTICAL 2021



AbbVie Inc. Rank 20 of 409

The relative strengths and weaknesses of AbbVie Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AbbVie Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 253% points. The greatest weakness of AbbVie Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 172%, being 526% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	24,173,000
Cost of Goods Sold	15,387,000
Intangible Assets	116,000,000
Liabilities, Current	28,661,000
Liabilities, Non-Current	0
Other Assets	5,144,000
Other Compr. Net Income	473,000
Other Expenses	-1,224,000
Other Liabilities	0
Other Net Income	-7,965,000
Property and Equipment	5,248,000
Research and Development	7,755,000
Revenues	45,804,000
Selling, General and Administrative Expense	11,299,000

Output Variable	Value in 1000 USD
Assets	150,565,000
Liabilities	28,661,000
Expenses	33,217,000
Stockholders Equity	121,904,000
Net Income	4,622,000
Comprehensive Net Income	4,858,500
Economic Capital Ratio	172%

